NCT06980623View on ClinicalTrials.gov

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

Active, not recruitingOBSERVATIONAL

Enrollment

26,000

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

June 1, 2025

Study Completion Date

September 1, 2025

Conditions

Type 2 DiabetesHeart Failure

Interventions

DRUG

Tirzepatide

Exposure group

DRUG

Semaglutide

Referent group

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER